Sheet \_ 1 \_ of \_ 5

ATTY. DOCKET NO. SERIAL NO. U.S. DEPARTMENT OF COMMERCE **FORM PTO-1449** 10/618,299 **A123 CON** PATENT AND TRADEMARK OFFICE **APPLICANT** CONFIRMATION NO. INFORMATION DISCLOSURE James G. Barsoum et 6907 STATEMENT BY APPLICANT al. GROUP-1653-1633 FILING DATE 07/11/03 U.S. PATENT DOCUMENTS

<u>·</u>		. 0	.S. FATERT DOCON	/ILIVIO		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RUK	3,710,795	01/16/73	Higuchi et al.	128	260	
	4,797,368	01/10/89	Carter et al.	435	320	
	5,262,564	11/16/93	Kun et al.	562	430	
RUK	5,399,346	03/21/95	Anderson et al.	424	93.21	
•						
,						
•				·	·	
· · · · · · · · · · · · · · · · · · ·						
					·	

#### . FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
RUK	WO 99/10516	03/04/99	PCT (WIPO)	C12N	15/86	123	NO
704/	_·	<del> </del>	<del> </del>	<del> </del>	†		
TAIK	WO 01/60377	08/23/01	PCT (WIPO)	A61K	31/66		
		,	<b></b>				
			·				
			<b></b>			·	
						•	
			<u> </u>				

EXAMINER TO A. Kell

DATE CONSIDERED

7/11/05

Sheet 2 of 5

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. A123 CON	SERIAL NO. 10/618,299
O 1 mm	FORMATION DISCLOSURE ATEMENT BY APPLICANT	APPLICANT James G. Barsoum et al.	CONFIRMATION NO. 6907
FEB 1		FILING DATE 07/11/03	GROUP 1663 1633

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
EXAMINER INITIAL	
RUK	R. Alemany, et al., "Blood Clearance Rates of Adenovirus Type 5 in Mice," Journal of General Virology, 81(11):2605-9 (2000).
	D. Armentano et al., "Effect of the E4 Region on the Persistence of Transgene Expression from Adenovirus Vectors," <i>Journal of Virology</i> , 71(3):2408-16 (1997).
	N. B. Beck, et al., "Baculovirus Vectors Repress Phenobarbital-Mediated Gene Induction and Stimulate Cytokine Expression in Primary Cultures of Rat Hepatocytes," <i>Gene Therapy</i> , 7(15):1274-83 (2000).
·	C. A. Bradham, et al., "Activation of Nuclear Factor-KappaB During Orthotopic Liver Transplantation in Rats is Protective and Does Not Require Kupffer Cells," <i>Liver Transplantation and Surgery</i> , 5(4):282-93 (1999).
	H. Chao, et al., "Several Log Increase in Therapeutic Transgene Delivery by Distinct Adeno-Associated Viral Serotype Vectors," <i>Molecular Therapy</i> , 2(6):619-623 (2000).
	H. Chen, et al. "Persistence in Muscle of an Adenoviral Vector that Lacks All Viral Genes," Proceedings of the National Academy of Sciences U.S.A., 94:1645-1650 (1997).
	T. Daemen, et al., "Liposomal Doxorubicin-Induced Toxicity: Depletion and Impairment of Phagocytic Activity of Liver Macrophages," <i>International Journal of Cancer</i> , 61(5):716-721 (1995).
	H. J. Delecluse, et al., "The Genetic Approach to the Epstein-Barr Virus: From Basic Virology to Gene Therapy," <i>Molecular Pathology</i> , 53(5):270-9 (2000).
	O. Devergne, et al., "In Vivo Expression of IL-1 Beta and IL-6 Genes During Viral Infections in Human," European Cytokine Network, 2(3):183-94 (1991).
	K. E. Drazan, et al., "Viral IL-10 Gene Therapy Inhibits TNF-Alpha and IL-1 Beta, Not IL-6, in the Newborn Endotoxemic Mouse," <i>Journal of Pediatric Surgery</i> , 31(3):411-4, (1996).
$\bigvee$	J. F. Engelhardt, et al., "Prolonged Transgene Expression in Cotton Rat Lung with Recombinant Adenoviruses Defective in E2a," Human Gene Therapy, 5 (10):1217-29 (1994).
TUK	J. L. Goldstein, et al., "Defective Lipoprotein Receptors and Atherosclerosis. Lessons From an Animal Counterpart of Familial Hypercholesterolemia," New England Journal of Medicine, 309(5):288-96 (1983).

**EXAMINER** 

Polano S. Kelly

DATE CONSIDERED

7/11/05

Sheet 3 of 5

FORM PTO-1449  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO A123 CON	SERIAL NO. 10/618,299
PE JCS INFORMATION DISCLOSURE	APPLICANT James G. Barsoum et al.	CONFIRMATION NO. 6907
FEB 2 7 2004 E	FILING DATE 07/11/03	GROUP 1 <del>653-</del> 1633
COTEM & TRADE	,	•

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) **EXAMINER** INITIAL S. Hegenbarth, et al., "Liver Sinusoidal Endothelial Cells Are Not Permissive for Adenovirus RUK Type 5," Human Gene Therapy, 11(3):481-6 (2000). W. S. Hu, et al., "Design of Retroviral Vectors and Helper Cells for Gene Therapy," Pharmacological Reviews, 52(4):493-511 (2000). S. Ishibashi, et al., "Hypercholesterolemia in Low Density Lipoprotein Receptor Knockout Mice and Its Reversal by Adenovirus-Mediated Gene Delivery," Journal of Clinical Investigation, 92(2):883-93 (1993). S. Ishibashi, et al., "Massive Xanthomatosis and Atherosclerosis in Cholesterol-Fed Low Density Lipoprotein Receptor-Negative Mice," Journal of Clinical Investigation, 93(5):1885-93 (1994). K. Jooss, et al., "Cyclophosphamide Diminishes Inflammation and Prolongs Transgene Expression Following Delivery of Adenoviral Vectors to Mouse Liver and Lung," Human Gene Therapy, 7(13):1555-66 (1996). K. Jooss, et al., "Blunting of Immune Responses to Adenoviral Vectors in Mouse Liver and Lung with CTLA4Ig," Gene Therapy, 5(3): 309-319 (1998). M. A. Kay, et al., "Transient Immunomodulation with anti-CD40 Ligand Antibody and CTLA4Ig Enhances Persistence and Secondary Adenovirus-Mediated Gene Transfer into Mouse Liver," Proceedings of the National Academy of Sciences U. S. A., 94: 4686-4691 (1997).M. A. Kay, et al., "Viral Vectors for Gene Therapy: The Art of Turning Infectious Agents Into Vehicles of Therapeutics," Nature Medicine, 7(1):33-40 (2001). N. Kuriyama, et al., "Pretreatment with Protease is a Useful Experimental Strategy for Enhancing Adenovirus-Mediated Cancer Gene Therapy," Human Gene Therapy, 11(16):2219-30 (2000). A. Lieber, et al., "The Role of Kupffer Cell Activation and Viral Gene Expression in Early Liver Toxicity after Infusion of Recombinant Adenovirus Vectors," Journal of Virology, 71(11):8798-8807 (1997).

**EXAMINER** 

Sheet 4 of 5

	• .				
FORM PTO-1	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. A123 CON	SERIAL NO. 10/618,299		
77200	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT James G. Barsoum et al.	CONFIRMATION NO 6907		
FEB 2 1 LLC		FILING DATE 07/11/03	GROUP <del>1653</del> 163		
CATEM & TRADE	OTHER DOCUMENTS (Including Author, Tit	lo Data Padinant Pages El	lo )		
EXAMINER INITIAL	OTHER DOCOMENTS (including Admor, the	ie, Date, reminent rages, L			
RUK	A. Lieber, et al., "Inhibition of NF-KappaB Ac Allows for Persistence of First-Generation Add Virology, 72 (11):9267-77 (1998).		-,·		
	S. Longman, et al., "Accumulation of Protein-Influence of Increasing Carrier Circulation Life Experimental Therapeutics, 275(3):1177-1184	etimes," Journal of Pharn			
	N. Morral, et al., "High Doses of a Helper-Dependent Adenoviral Vector Yield Supraphysiological Levels of Alphal-Antitrypsin with Negligible Toxicity," <i>Human Gene Therapy</i> , 9(18):2709-16 (1998).				
	X. Q. Qin, et al. "Interferon-β Gene Therapy In of Established Tumors in Immune-Deficient M. Sciences U. S. A., 95:14411-14416 (1998).	lice," Proceedings of the l	National Academy of		
	M. J. Parr, et al., "The Presence of G-MI in Lip Prevent RES Blockade," Biochimica et Biophy				
	G. Schieder, et al., "Genomic DNA Transfer win Improved <i>In Vivo</i> Gene Expression and Dec (1998).				
	W. M. Siders, et al., "T Cell- and NK Cell-Inde Systemic Administration of an IL-12-Expression Immunology, 160:5465-5474 (1998).	-	•		
	N. Somia and I. M. Verma, "Gene Therapy: Tr 1(2):91-9 (2000).	ials and Tribulations," Na	ture Reviews Genetic		
	K. Tanzawa, et al., "WHHL-Rabbit: A Low D Model For Familial Hypercholesterolemia," F.	·			
	N. Tao, et al., "Sequestration of Adenoviral Ve Response of Transduction in Liver," Molecular of Gene Therapy, 3(1):28-35 (2001).				
RMK	W. M. Tsui, et al., "Liver Changes in Reactive 12(6):363-7 (1992).	Haemophagocytic Syndro	ome," Liver,		
EXAMINER	7 3/K//	DATE CONSID	DERED 7/11/05		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Sheet <u>5</u> of <u>5</u>

FORMPTO-T	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. A123 CON	SERIAL NO. 10/618,299		
FEB 2 7 200	§) UNFORMATION DISCLOSURE ESTATEMENT BY APPLICANT	APPLICANT James G. Barsoum et al.	CONFIRMATION NO. 6907		
TRANS		FILING DATE 07/11/03	GROUP 1653 633		
	OTHER DOCUMENTS (Including Author, Title	e Date Perlinent Pages, Ft	c.)		
EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  R				
RUK	V. W. van Beusechem, et al., "Recombinant Adenovirus Vectors with Knobless Fibers for Targeted Gene Transfer," Gene Therapy, 7 (22):1940-6 (2000).				
	N. van Rooijen, et al., "Transient Suppression of Macrophage Functions by Liposome- Encapsulated Drugs," <i>Trends in Biotechnology</i> , 15(5):178-185 (1997).				
	S. Wang, et al., "Effect of Clodronate on Macrophage Depletion and Adenoviral-Mediated Transgene Expression in Salivary Glands," <i>Journal of Oral Pathology and Medicine</i> , 28(4):145-51 (1999)				
	J. M. Wilson, et al., "Cystic Fibrosis. Vehicles for Gene Therapy." Nature, 365(6448):691-2 (1993).				
RMK	G. Wolff, et al., "Enhancement of <i>In Vivo</i> Ader by Prior Depletion of Tissue Macrophages in the 71(1):624-9 (1997).				
**		· .			
•					
	·		· · · · · · · · · · · · · · · · · · ·		
EXAMINER	P = 1 V //	DATE CONSI	DERED 7/1/05		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.